The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Practice Bulletin No. 163: Screening for Fetal Aneuploidy
Abstract
Prenatal genetic screening is designed to assess whether a patient is at increased risk of having a fetus affected by a genetic disorder. In contrast, prenatal genetic diagnostic testing is intended to determine, with as much certainty as possible, whether a specific genetic disorder or condition is present in the fetus. The purpose of prenatal screening for aneuploidy is to provide an assessment of the woman's risk of carrying a fetus with one of the more common fetal aneuploidies. This is in contrast to prenatal diagnostic testing for genetic disorders, in which the fetal chromosomes are evaluated for the presence or absence of abnormalities in chromosome number, deletions, and duplications, or the fetal DNA is evaluated for specific genetic disorders. The wide variety of screening test options, each offering varying levels of information and accuracy, has resulted in the need for complex counseling by the health care provider and complex decision making by the patient. No one screening test is superior to other screening tests in all test characteristics. Each test has relative advantages and disadvantages. It is important that obstetrician-gynecologists and other obstetric care providers be prepared to discuss not only the risk of aneuploidy but also the benefits, risks, and limitations of available screening tests. Screening for aneuploidy should be an informed patient choice, with an underlying foundation of shared decision making that fits the patient's clinical circumstances, values, interests, and goals.The purpose of this Practice Bulletin is to provide current information regarding the available screening test options for fetal aneuploidy and to review their benefits, accuracy, and limitations. For information regarding prenatal diagnostic testing for genetic disorders, refer to Practice Bulletin No. 162, Prenatal Diagnostic Testing for Genetic Disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Presence of fetal DNA in maternal plasma and serum
Lo, Y. M. D., Corbetta, N., Chamberlain, P. F., Rai, V., Sargent, I. L., Redman, C. W., & Wainscoat, J. S. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02174-0 · Cited by 3,129
First-Trimester or Second-Trimester Screening, or Both, for Down's Syndrome
Malone, F. D., Canick, J. A., Ball, R. H., Nyberg, D. A., Comstock, C. H., Bukowski, R., Berkowitz, R. L., Gross, S. J., Dugoff, L., Craigo, S. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043693 · Cited by 1,081
Nicolaides, K. H., Azar, G., Byrne, D., Mansur, C., & Marks, K. (1992) · BMJ · doi:10.1136/bmj.304.6831.867 · Cited by 1,056
Palomaki, G. E., Kloza, E. M., Lambert-Messerlian, G. M., Haddow, J. E., Neveux, L. M., Ehrich, M., van den Boom, D., Bombard, A. T., Deciu, C., Grody, W. W., et al. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e3182368a0e · Cited by 939
Cell-free DNA Analysis for Noninvasive Examination of Trisomy
Norton, M. E., Jacobsson, B., Swamy, G. K., Laurent, L. C., Ranzini, A. C., Brar, H., Tomlinson, M. W., Pereira, L., Spitz, J. L., Hollemon, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407349 · Cited by 817
Gil, M. M., Quezada, M. S., Revello, R., Akolekar, R., & Nicolaides, K. H. (2015) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.14791 · Cited by 807
Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA Sequencing
Bianchi, D. W., Platt, L. D., Goldberg, J. D., Abuhamad, A. Z., Sehnert, A. J., & Rava, R. P. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31824fb482 · Cited by 644
Dugoff, L., Hobbins, J. C., Malone, F. D., Porter, T. F., Luthy, D., Comstock, C. H., Hankins, G., Berkowitz, R. L., Merkatz, I., Craigo, S. D., et al. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.06.052 · Cited by 624
DNA Sequencing versus Standard Prenatal Aneuploidy Screening
Bianchi, D. W., Parker, R. L., Wentworth, J., Madankumar, R., Saffer, C., Das, A. F., Craig, J. A., Chudova, D. I., Devers, P. L., Jones, K. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311037 · Cited by 620
Norton, M. E., Brar, H., Weiss, J., Karimi, A., Laurent, L. C., Caughey, A. B., Rodriguez, M. H., Williams, J., Mitchell, M. E., Adair, C. D., et al. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.05.021 · Cited by 596
Cited by
Gregg, A. R., Skotko, B. G., Benkendorf, J. L., Monaghan, K. G., Bajaj, K., Best, R. G., Klugman, S., & Watson, M. S. (2016) · Genetics in Medicine · doi:10.1038/gim.2016.97 · Cited by 683
Sequencing of Circulating Cell-free DNA during Pregnancy
Bianchi, D. W., & Chiu, R. W. K. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705345 · Cited by 313
Implementation of obstetric telehealth during COVID-19 and beyond
Fryer, K., Delgado, A., Foti, T., Reid, C. N., & Marshall, J. (2020) · Maternal and Child Health Journal · doi:10.1007/s10995-020-02967-7 · Cited by 273
CRISPR/cas systems redefine nucleic acid detection: Principles and methods
Wang, M., Zhang, R., & Li, J. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112430 · Cited by 268
Buijtendijk, M. F., Bet, B. B., Leeflang, M. M., Shah, H., Reuvekamp, T., Goring, T., Docter, D., Timmerman, M. G., Dawood, Y., Lugthart, M. A., et al. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014715.pub2 · Cited by 47
Metadata
- Venue
- Obstetrics & Gynecology
- Published
- 2016-05
- Volume
- 127
- Issue
- 5
- Pages
- e123-e137
- ISSN
- 0029-7844 (ISSN-L)
- OpenAlex
- W4251245750
- Cited by
- 273
- References
- 43
- FWCI
- 39.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Practice Bulletin No. 163: Screening for Fetal Aneuploidy. https://app.cochat.ai/papers/10.1097/aog.0000000000001406
- The paper
- Practice Bulletin No. 163: Screening for Fetal Aneuploidy. (2016). Obstetrics & Gynecology. https://doi.org/10.1097/aog.0000000000001406
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.